National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Trastuzumab emtansine (Kadcyla®) HTA ID: 20002

Trastuzumab emtansine (Kadcyla®) is indicated as a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.


NCPE Assessment Process Complete
Rapid review commissioned 20/01/2020
Rapid review completed 27/02/2020
Rapid Review outcome A full HTA is recommended to assess the clinical and cost effectiveness of trastuzumab emtansine compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 04/03/2020
Pre-submission consultation with Applicant 31/03/2020
Full submission received from Applicant 08/06/2020
Preliminary review sent to Applicant 29/10/2020
NCPE assessment re-commenced 30/11/2020
Factual accuracy sent to Applicant 11/02/2021
NCPE assessment re-commenced 17/02/2021
NCPE assessment completed 12/03/2021
NCPE assessment outcome The NCPE recommends that trastuzumab emtansine (Kadcyla®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.